{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:20:06Z","timestamp":1760059206190,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Nirmatrelvir plus ritonavir (NPR) has been approved for treating mild to moderate COVID-19 in high-risk adults but concerns about rebound effects have limited its use. This study aimed to identify individuals at risk of seeking medical care among high-risk non-hospitalized patients treated with NPR from 1 January 2022 to 31 December 2022, at our institution. Our outcome variable was the composite of subsequent evaluation in the Emergency Department or inpatient admission within four weeks of their NPR treatment. Of 369 patients who received NPR treatment, the mean (SD) age was 59.3 (\u00b113.8) years; 64% (236) were female, and 77.7% (281) were white. The incidence of the composite event was 6.8% (25\/369). In multivariable logistic regression, factors for seeking medical care following NPR treatment were female sex (OR 4.6; 95% CI 1.4\u201315.3; p = 0.013), myocardial infarction (OR 4.1; 95% CI 1.4\u201311.8; p = 0.011), chronic lung disease (CLD) except asthma and chronic obstructive pulmonary disease (COPD) (OR = 3.9, 95% CI 1.1\u201313.5; p = 0.03), and diabetes mellitus with complications (OR 6.9; 95% CI 2.0\u201323.3; p = 0.002) while alcohol users (OR 0.39; 95% CI 0.2\u20130.9; p = 0.038) were less likely to seek medical care. Larger cohorts are necessary to further assess and confirm these risk factors.<\/jats:p>","DOI":"10.3390\/v17060782","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:07:58Z","timestamp":1748592478000},"page":"782","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: \u201cSymptom Rebound\u201d"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6326-0908","authenticated-orcid":false,"given":"Ashish","family":"Bhargava","sequence":"first","affiliation":[{"name":"Department of Medicine, Thomas Mackey Center for Infectious Disease Research, Henry Ford St. John Hospital, 19251 Mack Avenue, Suite 340, Grosse Pointe Woods, MI 48236, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Szpunar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Mackey Center for Infectious Disease Research, Henry Ford St. John Hospital, 19251 Mack Avenue, Suite 340, Grosse Pointe Woods, MI 48236, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1232-0485","authenticated-orcid":false,"given":"Mamta","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Mackey Center for Infectious Disease Research, Henry Ford St. John Hospital, 19251 Mack Avenue, Suite 340, Grosse Pointe Woods, MI 48236, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Saravolatz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Thomas Mackey Center for Infectious Disease Research, Henry Ford St. John Hospital, 19251 Mack Avenue, Suite 340, Grosse Pointe Woods, MI 48236, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"ref_1","first-page":"2118","article-title":"FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, non-hospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"(2024, July 27). Paxlovid Prescribing Concerns for People 65+ Revealed in Medscape Survey. Available online: https:\/\/www.medscape.com\/viewarticle\/987121?form=fpf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1001\/jama.2022.9925","article-title":"From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"key":"ref_5","first-page":"e26239","article-title":"COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature","volume":"14","author":"Alshanqeeti","year":"2022","journal-title":"Cureus"},{"key":"ref_6","unstructured":"(2024, July 28). HAN Archive-00467. COVID-19 Rebound After Paxlovid Treatment. [May 2022], Available online: https:\/\/emergency.cdc.gov\/han\/2022\/han00467.asp."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1093\/cid\/ciac481","article-title":"Rebound Phenomenon After Nirmatrelvir\/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons","volume":"76","author":"Ranganath","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1473-3099(22)00873-8","article-title":"Viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong: A population-wide retrospective cohort study","volume":"23","author":"Wong","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMc2205944","article-title":"EPIC-HR Trial Investigators. Nirmatrelvir-Ritonavir and Viral Load Rebound in COVID-19","volume":"387","author":"Anderson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciad102","article-title":"The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus Ritonavir Versus Untreated Controls","volume":"77","author":"Pandit","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jfma.2023.02.008","article-title":"Factors associated with viral rebound among COVID-19 patients receiving oral antivirals","volume":"122","author":"Chen","year":"2023","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/cid\/ciac663","article-title":"Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following nirmatrelvir\/ritonavir treatment","volume":"76","author":"Epling","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.7326\/M23-1756","article-title":"SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: An observational study","volume":"176","author":"Edelstein","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/10428194.2023.2183732","article-title":"Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with nirmatrelvir\/ritonavir or Molnupiravir","volume":"64","author":"Tadmor","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.15585\/mmwr.mm7251a1","article-title":"SARS-CoV-2 Rebound with and Without Use of COVID-19 Oral Antivirals","volume":"72","author":"Smith","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1093\/cid\/ciac496","article-title":"Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir\/Ritonavir Treatment","volume":"76","author":"Carlin","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/cid\/ciaa674","article-title":"Predictors for Severe COVID-19 Infection","volume":"71","author":"Bhargava","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/08850666211001799","article-title":"Clinical Features and Risk Factors for In-Hospital Mortality from COVID-19 Infection at a Tertiary Care Medical Center, at the Onset of the US COVID-19 Pandemic","volume":"36","author":"Bhargava","year":"2021","journal-title":"J. Intensive Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bucholc, M., Bradley, D., Bennett, D., Patterson, L., Spiers, R., Gibson, D., Van Woerden, H., and Bjourson, A.J. (2022). Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-20176-w"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1017\/ice.2020.1390","article-title":"Predictors for in-hospital mortality from coronavirus disease 2019 (COVID-19) infection among adults aged 18-65 years","volume":"42","author":"Bhargava","year":"2021","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e4005","DOI":"10.1093\/cid\/ciaa1468","article-title":"Risk Factors for In-hospital Mortality from Coronavirus Disease 2019 Infection Among Black Patients-An Urban Center Experience","volume":"73","author":"Bhargava","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2335077","DOI":"10.1001\/jamanetworkopen.2023.35077","article-title":"Nirmatrelvir or Molnupiravir Use and Severe Outcomes from Omicron Infections","volume":"6","author":"Lin","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccm.2022.11.013","article-title":"COVID-19 in Patients with Chronic Lung Disease","volume":"44","author":"Calver","year":"2023","journal-title":"Clin. Chest Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.anai.2020.05.001","article-title":"Asthma, biologics, corticosteroids, and coronavirus disease 2019","volume":"125","author":"Akenroye","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","article-title":"COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives","volume":"17","author":"Nishiga","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2337\/dc18-0287","article-title":"Glycemic Control and Risk of Infections Among People with Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study","volume":"41","author":"Critchley","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes","volume":"31","author":"Zhu","year":"2020","journal-title":"Cell Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e131774","DOI":"10.1172\/jci.insight.131774","article-title":"Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection","volume":"4","author":"Kulcsar","year":"2019","journal-title":"JCI Insight"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wang, L., Berger, N.A., Davis, P.B., Kaelber, D.C., Volkow, N.D., and Xu, R. (2022). COVID-19 rebound after Paxlovid and Molnupiravir during January\u2013June 2022. medRxiv, preprint.","DOI":"10.1101\/2022.06.21.22276724"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wu, C., and Qian, Y. (2022). The gender peak effect: Women are most vulnerable to infections during COVID-19 peaks. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.937179"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1038\/s41467-020-19741-6","article-title":"Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission","volume":"11","author":"Peckham","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1017\/ash.2021.223","article-title":"Do risk factors at the time of hospital admission differ by sex for in-hospital mortality from coronavirus disease 2019 (COVID-19)?","volume":"1","author":"Sharma","year":"2021","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and Gender Differences in the Outcomes of Vaccination over the Life Course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Dai, X.-J., Tan, L., Ren, L., Shao, Y., Tao, W., and Wang, Y. (2022). COVID-19 Risk Appears to Vary Across Different Alcoholic Beverages. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.772700"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/nu4070759","article-title":"Wine, beer, alcohol and polyphenols on cardiovascular disease and cancer","volume":"4","author":"Arranz","year":"2012","journal-title":"Nutrients"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Radonji\u0107, S., Mara\u0161, V., Rai\u010devi\u0107, J., and Ko\u0161merl, T. (2020). Wine or Beer? Comparison, Changes and Improvement of Polyphenolic Compounds during Technological Phases. Molecules, 25.","DOI":"10.3390\/molecules25214960"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bbi.2020.05.059","article-title":"Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK","volume":"87","author":"Hamer","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4049\/jimmunol.181.1.641","article-title":"Chronic alcohol consumption increases the severity of murine influenza virus infections","volume":"181","author":"Meyerholz","year":"2008","journal-title":"J. Immunol."},{"key":"ref_40","first-page":"153","article-title":"Alcohol and the Immune System","volume":"37","author":"Sarkar","year":"2015","journal-title":"Alcohol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.pnpbp.2015.09.001","article-title":"Opposing effects of alcohol on the immune system","volume":"65","author":"Barr","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/6\/782\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:43:26Z","timestamp":1760031806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/6\/782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["v17060782"],"URL":"https:\/\/doi.org\/10.3390\/v17060782","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}